| 17 |
Leszinski G, Lehner J, Gezer U, et al. Increased DNA integrity in colorectal cancer[J]. In Vivo, 2014,28(3):299-303.
|
| 18 |
Madhavan D, Wallwiener M, Bents K, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat,2014,146(1):163-174.
|
| 19 |
Gao YJ, He YJ, Yang ZL, et al. Increased integrity of circulating cellfree DNA in plasma of patients with acute leukemia[J]. Clin Chem Lab Med, 2010,48(11):1651-1656.
|
| 20 |
Da Siliva Fihe BF, Gurgel AP, Neto MA, et al. Circulating cell-free DNA in serum as a biomarker of colorectal cancer[J]. J Clin Pathol,2013,66(9):775-778.
|
| 21 |
Sriram KB, Relan V, Clarke BE, et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas[J]. BMC Cancer, 2012,12:428.
|
| 22 |
Rolfo C, Castiglia M, Hong D, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers[J]. Biochim Biophys Acta,2014,1846(2):539-546.
|
| 23 |
Lavon I, Refael M, Zelikovitch B, et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades[J]. Neuro Oncol, 2010,12(2):173-180.
|
| 24 |
Sriram KB, Relan V, Clarke BE, et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas[J]. BMC Cancer, 2012,12:428.
|
| 25 |
Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay[J]. PLoS One, 2008,3(11):e3759.
|
| 26 |
Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer[J]. BMC Med,2011,9:133.
|
| 27 |
Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut, 2014,63(2):317-325.
|
| 28 |
Bearzatto A, Conte D, Frattini M, et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer[J]. Clin Cancer Res, 2002,8(12):3782-3787.
|
| 29 |
Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer[J]. Cancer Lett,2011,303(1):21-28.
|
| 30 |
Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients[J]. Lung Cancer,2013,81(3):397-403.
|
| 31 |
Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma[J]. J Thorac Oncol, 2011,6(10):1632-1638.
|
| 32 |
Powrozek T, Krawczyk P, Kucharczyk T, et al. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report[J]. Med Oncol, 2014,31(4):917.
|
| 33 |
Nones K, Waddell N, Song S, et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling[J]. Int J Cancer, 2014,135(5):1110-1118.
|
| 34 |
Zhang Q, Hu G, Yang Q, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA[J]. Gynecol Oncol, 2013,130(1):132-139.
|
| 35 |
Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection[J].Ann Surg Treat Res, 2014,83(3)136-142.
|
| 36 |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med,2013,368(13):1199-1209.
|
| 37 |
Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA[J]. Sci Transl Med, 2012,4(136): 136ra168.
|
| 38 |
Lecomte T, Berger A, Zinzindohoue F, et al. Detection of freecirculating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis[J]. Int J Cancer,2002,100(5):542-548.
|
| 39 |
Spindler KL, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan[J]. Clin Cancer Res, 2012,18(4):1177-1185.
|
| 40 |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med,2013,368(13):1199-1209.
|
| 41 |
Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma[J]. Int J Cancer, 2014,134(5):1207-1213.
|
| 42 |
Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012,18(8):2391-2401.
|
| 43 |
Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing[J]. Science, 2014,346(6206):256-259.
|
| 44 |
Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing[J]. Nat Genet, 2014,46(3):225-233.
|
| 1 |
Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res,1977,37(3):646-650.
|
| 2 |
Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients[J]. Oncology,1989,46(5):318-322.
|
| 3 |
Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer[J]. Clin Cancer Res, 2005,11(3):1219-1225.
|
| 4 |
Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res, 2001,61(4):1659-1665.
|
| 5 |
Stroun M, Lyautey J, Lederrey C, et al. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells[J]?Ann N Y Acad Sci, 2001,945:258-264.
|
| 6 |
Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008,14(9):985-990.
|
| 7 |
Yu SC, Lee SW, Jiang P, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing[J].Clin Chem, 2013,59(8):1228-1237.
|
| 8 |
Cherepanova AV, Tamkovich SN, Bryzgunova OE, et al.Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors[J]. Ann N Y Acad Sci,2008,1137:218-221.
|
| 9 |
Lee TH, Montalvo L, Chrebtow V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma[J]. Transfusion, 2001,41(2):276-282.
|
| 10 |
Sonnenberg A, Marciniak JY, Rassenti L, et al. Rapid electrokinetic isolation of cancer-related circulating cell-Free DNA directly from blood[J]. Clin Chem, 2014,60(3):500-509.
|
| 11 |
Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum[J]. Clin Chim Acta,2009,404(2):100-104.
|
| 12 |
Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification[J]. Anal Bioanal Chem, 2014,406(26):6499-6512.
|
| 13 |
Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients[J]. Clin Chem, 2013,59(12): 1722-1731.
|
| 14 |
Chandrananda D, Thorne NP, Bahlo M. High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA[J]. BMC Med Genomics, 2015,8:29.
|
| 15 |
Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA[J]. Clin Cancer Res, 2014,20(6):1698-1705.
|
| 16 |
Yoruker EE, Ozgur E, Keskin M, et al. Assessment of circulating serum DNA integrity in colorectal cancer patients[J]. Anticancer Res,2015,35(4):2435-2440.
|
| 45 |
Swanton C. Intratumor Heterogeneity: Evolution through Space and Time[J]. Cancer Res, 2012,72(19):4875-4882.
|
| 46 |
Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer[J]. J Clin Oncol, 2012,30(6):587-592.
|
| 47 |
Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma[J]. J Clin Oncol, 2012,30(20):2522-2529.
|
| 48 |
Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers[J].Nature, 2012,486(7404):537-540.
|